Advisors Preferred’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Advisors Preferred’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-244	Closed	-$15.3K	–	234
2023 Q1	$15.3K	Buy	+244	New	+$15.7K	0.01%	155
2020 Q3	–	Sell	-125	Closed	-$7K	–	157
2020 Q2	$7K	Buy	+125	New	+$6.81K	﹤0.01%	133
2019 Q2	–	Sell	-891	Closed	-$49K	–	272
2019 Q1	$49K	Buy	+891	New	+$47.1K	0.02%	152
2017 Q3	–	Sell	-331	Closed	-$15K	–	269
2017 Q2	$15K	Buy	+331	New	+$14.3K	0.01%	194
2015 Q4	–	Sell	-185	Closed	-$8K	–	244
2015 Q3	$8K	Sell	185 -486	-72%	-$27.2K	0.01%	153
2015 Q2	$39K	Buy	+671	New	+$38.4K	0.02%	134
2014 Q4	–	Sell	-1,013	Closed	-$46.8K	–	322
2014 Q3	$46.8K	Sell	1,013 -633	-38%	-$28.5K	0.03%	143
2014 Q2	$71.9K	Sell	1,646 -6,316	-79%	-$256K	0.04%	134
2014 Q1	$331K	Buy	7,962 +4,161	+109%	+$178K	0.15%	114
2013 Q4	$140K	Buy	+3,801	New	+$136K	0.08%	110

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

IFWM

Institute for Wealth Management Denver, Colorado $938M AUM 29.36% 1-Year Est. Return

Advisors Preferred's PBE Position: Q2 2023 in Review

Advisors Preferred sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2023, closing a stake of 244 shares — an estimated $15.3K sold.

Advisors Preferred first reported a position in PBE in Q4 2013 and held it in 10 quarters. The position peaked at $331K in Q1 2014. 96 funds tracked by Wall St. Rank hold PBE as of Q2 2023.

Advisors Preferred reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2023 after selling out during the quarter.
Advisors Preferred sold 244 Invesco Biotechnology & Genome ETF shares in Q2 2023, an estimated $15.3K.
Advisors Preferred first reported a position in Invesco Biotechnology & Genome ETF in Q4 2013 and held it in 10 quarters.
Advisors Preferred's Invesco Biotechnology & Genome ETF position peaked at $331K in Q1 2014.
96 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2023.

Based on Advisors Preferred's 13F filing for Q2 2023, filed 4 Aug 2023.